MedTrace Logo

An Exploratory Clinical Study of BC006 in Patients With Advanced Solid Tumors

NCT05212896 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2022-01-28

No results posted yet for this study

Summary

This is a first in human, open-label, exploratory phase I clinical study including dose escalation (Ia) and dose expansion (Ib) stage. It aims to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BC006 in giant cell tumor of tendon sheath (GCTTS) and other advanced solid tumors.

Conditions

  • Advanced Solid Tumors (Including GCTTS)

Interventions

DRUG

BC006

BC006 monoclonal antibody injection

Sponsors & Collaborators

  • West China Hospital

    collaborator OTHER

  • Dragonboat Biopharmaceutical Company Limited

    lead INDUSTRY

Principal Investigators

  • Li Zheng · West China Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-11-26
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05212896 on ClinicalTrials.gov